Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

2

Revenue 2014

Pfizer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Pfizer's 2013 sales performance.

US biotech Translate Bio appoints Daniella Beckman

US biotech Translate Bio appoints Daniella Beckman

She has also held various finance positions at Coley Pharmaceuticals - which was acquired by Pfizer in 2008 - and Biogen Idec.

CHMP recommends Teva's generic version of Astellas' Advagraf

CHMP recommends Teva's generic version of Astellas' Advagraf The committee also recommended that Faslodex could be used in combination with Pfizer ’s breast cancer drug Ibrance (palbociclib) to treat hormone receptor positive, human epidermal growth factor receptor 2-negative

Roche wins CHMP nod for Alecensa licence extensions

Roche wins CHMP nod for Alecensa licence extensions The Committee also recommended Alecensa’s licence be extended to encompass second-line therapy in cases where Pfizer ’s personalised NSCLC treatment Xalkori (crizotinib) can’t be used.

Cellectis’ Mathieu Simon will serve as interim chief medical officer

Cellectis’ Mathieu Simon will serve as interim chief medical officer His other roles include senior vice president, global pharma operations for Pierre Fabre and has held numerous senior roles with Wyeth Pharmaceuticals, before it was acquired by Pfizer for $68bn back

NICE backs Pfizer’s Xeljanz for RA

NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’ s Xeljanz for RA. But UK’s cost-effectiveness watchdog removes two drugs from CDF. ... Pfizer is celebrating a positive recommendation from the National Institute for Health and Care Excellence (NICE) for Xeljanz (tofacitinib

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Pfizer
Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA
US revenue 2014
1: Gilead Sciences
2: Johnson & Johnson
3: Pfizer
4: Roche
5: Novartis
6: Amgen
7: Merck & Co.
8: Sanofi
9: AbbVie
10: Actavis
11: AstraZeneca
12: GlaxoSmithKline
13: Lilly
14: Bristol-Myers Squibb
15: Novo Nordisk
Oncology revenue 2014
1: Roche
2: Novartis
3: Celgene
4: Johnson & Johnson
5: Bristol-Myers Squibb
6: Lilly
7: Takeda
8: AstraZeneca
9: Merck & Co.
10: Amgen
11: Pfizer
12: Astellas
13: Bayer
14: Otsuka
15: Sanofi
16: Merck KGaA
17: Eisai
18: AbbVie
19: Pharmacyclics
20: Incyte
Immunology revenue 2014
1: AbbVie
2: Johnson & Johnson
3: Pfizer
4: Amgen
5: Merck & Co.
6: Astellas
7: Roche
8: Novartis
9: Bristol-Myers Squibb
10: Mitsubishi Tanabe
11: UCB
12: Hisamitsu
13: Daiichi Sankyo
14: Takeda
CNS revenue 2014
1: Pfizer
2: Biogen Idec
3: Novartis
4: Otsuka
5: Teva
6: Johnson & Johnson
7: Lilly
8: Merck KGaA
9: AstraZeneca
10: Shire
11: Bristol-Myers Squibb
12: UCB
13: Lundbeck
14: Eisai
15: GlaxoSmithKline
16: Sanofi
17: Mylan
18: Indivior
19: Actavis
20: Bayer
Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company
Biologic revenue 2014
1: Roche
2: Amgen
3: Novo Nordisk
4: AbbVie
5: Sanofi
6: Johnson & Johnson
7: Pfizer
8: Merck & Co.
9: Lilly
10: Biogen Idec
11: Merck KGaA
12: GlaxoSmithKline
13: Bristol-Myers Squibb
14: Novartis
15: Bayer

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Digital
Tools for the digital world
The next step for the pharma industry...
How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...

Infographics